# Identification of Age and Underlying Disease Characteristics in Patients with Mild to Moderate Depression Comorbid with Parkinson’s Disease: A Retrospective Case-control Study

## TL;DR

This study found that patients with Parkinson’s disease and mild to moderate depression tend to have an earlier disease onset, worse mood symptoms, and cognitive issues compared to those without depression.

## Contribution

The study identifies specific age and disease characteristics linked to depression in Parkinson’s disease patients, emphasizing the need for tailored management.

## Key findings

- Patients with mild to moderate depression had a significantly lower age of Parkinson’s disease onset.
- Depressed patients showed worse mood, cognitive performance, and longer disease duration.
- Statistical analysis confirmed associations between depression and cognitive and affective symptoms in Parkinson’s disease.

## Abstract

Depression is a widely recognized neuropsychiatric condition that often occurs as a comorbidity with various medical illnesses, including neurodegenerative disorders like Parkinson’s disease (PD). This study aimed to identify the age of onset and underlying disease characteristics associated with patients exhibiting mild to moderate depression comorbid with PD.

This retrospective case-control study included 114 elderly patients (age ≥65 years) diagnosed with Parkinson’s disease. The patients were divided into two groups: the non-depressed group (n = 65) and the mild to moderate depression group (n = 49). Patients’ emotional and affective symptoms, cognitive function, and clinical characteristics were assessed using standardized scales. Statistical analyses, including chi-square tests, Wilcoxon rank-sum tests, and logistic regression analysis, were performed to evaluate associations and correlations between the variables of interest.

Our findings revealed that patients in the mild to moderate depression group exhibited a significantly lower onset age of PD (52.33 ± 3.87 years) compared to the non-depressed group (59.27 ± 3.62 years, p < 0.001). Furthermore, patients with mild to moderate depression showed significantly higher scores in mood and affective symptoms measures, including the Hamilton Anxiety Scale (HAM-A) (p < 0.001) and Apathy Scale (p < 0.001). Additionally, the duration of Parkinson’s disease was significantly longer in the mild to moderate depression group (6.78 ± 2.01 years) compared to the non-depressed group (3.45 ± 1.52 years, p < 0.001). Similarly, patients in the mild to moderate depression group exhibited significantly poorer performance on the Mini-Mental State Examination (MMSE) (p < 0.001), Montreal Cognitive Assessment (MoCA) (p = 0.025), verbal fluency (p < 0.001), and Trail Making Test (p = 0.005). Additionally, correlation and logistic regression analysis revealed associations and predictive value of these variables with the presence of mild to moderate depression in Parkinson’s disease.

The study highlights the complex interaction of age and underlying disease characteristics in patients with mild to moderate depression comorbid with Parkinson’s disease. Early recognition and tailored management of depressive symptoms, mood and affective disturbances, cognitive impairment, and disease-specific characteristics are crucial for optimizing patient care and improving outcomes in individuals with Parkinson’s disease. These findings underscore the need for a comprehensive, patient-centered approach that considers the diverse interaction of demographic, clinical, and cognitive variables.